Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Implementation of genetic testing in breast cancer patients

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC

Breast cancer screening and treatment in Brazil

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer

Oral paclitaxel with encequidar in metastatic breast cancer

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients